Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Glitazones clinical data: an update].

B Guerci1

  • 1Service de Diabétologie, Maladies Métaboliques et Maladies de la Nutrition, CIC/INSERM, CHU de Nancy, Hôpital Jeanne d'Arc, 54201 Toul Cedex, BP 303, France. b.guerci@chu-nancy.fr

Annales D'Endocrinologie
|June 17, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Practical implementation of automated insulin delivery systems in 2025: A French position statement update.

Diabetes & metabolism·2025
Same author

Discovery of a TRMT10A mutation in a case of atypical diabetes: Case report.

Diabetes & metabolism·2024
Same author

Cutaneous hypersensitivity reaction to dulaglutide: A case report of an allergic reaction.

Diabetes & metabolism·2024
Same author

Practical implementation of automated closed-loop insulin delivery: A French position statement.

Diabetes & metabolism·2020
Same author

Nuclear power plant: state of knowledge of the population living in the area of the Cattenom special intervention plan. A cross-sectional study.

Journal of radiological protection : official journal of the Society for Radiological Protection·2020
Same author

Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings.

Diabetes & metabolism·2019
Same journal

Corrigendum to 'Pink adipose tissue: A paradigm of adipose tissue plasticity' [Ann. Endocrinol. 85 (2004) 248-51].

Annales d'endocrinologie·2026
Same journal

Intraoperative location of parathyroid glands during total thyroidectomy: a systematic review of the literature according to the PRISMA method.

Annales d'endocrinologie·2026
Same journal

Clinical and genetic diagnosis of PHP1A associated with hypogonadism in a young male: A case report.

Annales d'endocrinologie·2026
Same journal

Autoimmune features in acquired generalized lipodystrophy and anti-perilipin 1 antibodies: A case report.

Annales d'endocrinologie·2026
Same journal

The diagnostic challenge of occult glucocorticoid exposure causing Cushing's syndrome.

Annales d'endocrinologie·2026
Same journal

ACTH-dependent Cushing's syndrome in MEN1: When multiple tumors complicate the diagnosis.

Annales d'endocrinologie·2026
See all related articles

Thiazolidinediones (glitazones) are new oral diabetes drugs. Recent studies clarify their use, benefits, and potential to protect pancreatic cells and prevent type 2 diabetes.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Thiazolidinediones (glitazones) represent a recent class of oral antidiabetic agents.
  • Understanding their mechanism of action has advanced through in vitro and animal studies.
  • Type 2 diabetes is characterized by progressive beta-pancreatic cell dysfunction.

Purpose of the Study:

  • To review and discuss recent studies on thiazolidinediones.
  • To elucidate the mechanism of action of glitazones.
  • To define the optimal use and conditions for glitazone therapy in type 2 diabetes.

Main Methods:

  • Review of recent in vitro and animal model studies.
  • Analysis of long-term, controlled clinical trials.
  • Evaluation of monotherapy and combination therapy with metformin or sulfonylureas.

Related Experiment Videos

Main Results:

  • Glitazones demonstrate beneficial metabolic effects.
  • Studies provide insights into their mechanism of action.
  • Clinical trials define their place in therapy, including adverse event profiles.
  • Potential for preserving beta-pancreatic cell function and delaying diabetes onset.

Conclusions:

  • Thiazolidinediones are valuable oral agents for type 2 diabetes management.
  • Their use, particularly in combination therapy, is supported by recent evidence.
  • Glitazones hold promise for preventing beta-cell decline and type 2 diabetes progression.